ArticleClinical case reports2026
Nipple-Originating Solid Papillary Carcinoma In Situ: A Case Report and Literature Review.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nipple-Originating Solid Papillary Carcinoma In Situ: A Case Report and Literature Review.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid papillary carcinoma of the breast is a rare histopathological subtype of papillary neoplasms, and its in situ variant localized to the nipple is particularly uncommon. Current oncology literature provides limited evidence on standardized diagnostic criteria, biological behavior, and optimal treatment strategies for this entity. We describe a 73-year-old Chinese woman with a two-year history of a left nipple mass that developed erythema and ulceration five days prior to presentation. Imaging studies (ultrasonography and MRI) identified an isolated nipple lesion (BI-RADS 4b) with no other breast tissue involvement. Wide local excision confirmed solid papillary carcinoma in situ (pTisN0M0), with pathological evaluation showing R0 resection margins. The patient received standard adjuvant endocrine therapy (letrozole 2.5 mg/day) and showed no evidence of recurrence at 9 month follow-up. For patients with nipple-confined solid papillary carcinoma lacking high-risk features, complete surgical excision constitutes the mainstay of treatment, complemented by postoperative adjuvant endocrine therapy to mitigate recurrence risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.